Updated Recommendations for Use of MenB-FHbp Serogroup B Meningococcal Vaccine — Advisory Committee on Immunization Practices, 2016

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Patton, Monica E. ; Stephens, David ; Moore, Kelly ; MacNeil, Jessica R.
• Corporate Authors:
  United States. Advisory Committee on Immunization Practices.
• Description:
  Two serogroup B meningococcal (MenB) vaccines are currently licensed for use in persons aged 10-25 years in the United States. The two vaccines are MenB-FHbp (Trumenba, Pfizer, Inc.) (1) and MenB-4C (Bexsero, GlaxoSmithKline Biologicals, Inc.) (2). In February 2015, the Advisory Committee on Immunization Practices (ACIP) recommended use of MenB vaccines among certain groups of persons aged ≥10 years who are at increased risk for serogroup B meningococcal disease* (Category A) (3), and in June 2015, ACIP recommended that adolescents and young adults aged 16-23 years may be vaccinated with MenB vaccines to provide short-term protection against most strains of serogroup B meningococcal disease (Category B|) (4). Consistent with the original Food and Drug Administration (FDA) licensure for the two available MenB vaccines, ACIP recommended either a 3-dose series of MenB-FHbp or a 2-dose series of MenB-4C. Either MenB vaccine can be used when indicated; ACIP does not state a product preference. The two MenB vaccines are not interchangeable; the same vaccine product must be used for all doses in a series. In April 2016, changes to the dosage and administration of MenB-FHbp were approved by FDA to allow for both a 2-dose series (administered at 0 and 6 months) and a 3-dose series (administered at 0, 1-2, and 6 months) (5,6). In addition, the package insert now states that the choice of dosing schedule depends on the patient's risk for exposure and susceptibility to serogroup B meningococcal disease. These recommendations are regarding use of the 2- and 3-dose schedules of MenB-FHbp vaccine (Trumenba) and replace previous ACIP recommendations for use of MenB-FHbp vaccine published in 2015 (3,4). Recommendations regarding use of MenB-4C (Bexsero) are unchanged (3,4).
• Subjects:
  Adolescent Advisory Committees Child Full Report Humans Immunization Immunization Schedule Meningococcal Infections Meningococcal Vaccines Neisseria Meningitidis, Serogroup B Young Adult

  More +
• Source:
  MMWR Morbidity Mortal Weekly Rep. 66(19):509-513.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6619a6
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  28520709
• Pubmed Central ID:
  PMC5657641
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Location:
  North America
• Pages in Document:
  5 pdf pages
• Volume:
  66
• Issue:
  19
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR) Advisory Committee on Immunization Practices (ACIP)
• Main Document Checksum:
  urn:sha-512:66c7460d62feb8d2a1b15624e2b16ac96161e51a5c003065f0e4794726c489b5726bbd51ff5d72c2b6ff99097e57aab7b874eff18427c64b0c44041677c3ae40
• Download URL:
  https://stacks.cdc.gov/view/cdc/54494/cdc_54494_DS1.pdf
• File Type:
  [PDF - 142.10 KB ]